Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 299 free, full-text research articles on human participants. First 3 results:

Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
 

Author(s): Chunxiang Cao, Meng Kuang, Wei Xu, Xunlei Zhang, Jinfei Chen, Cuiju Tang

Journal: Jpn. J. Clin. Oncol.. 2015 Dec;45(12):1122-30.

 

Gemcitabine-based chemotherapy is widely used for unresectable advanced pancreatic cancer which contains locally advanced and metastatic pancreatic cancer. We performed meta-analysis to examine whether gemcitabine plus S-1 could improve treatment efficacy as first-line chemotherapy ...

Last Updated: 20 Nov 2015

Go To URL
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
 

Author(s): H Sugimoto, M Nakamura, H Yoda, K Hiraoka, K Shinohara, M Sang, K Fujiwara, O Shimozato, H Nagase, T Ozaki

Journal:

 

Last Updated: 16 Oct 2015

Go To URL
Reverse correlation of Jab1 and Smad4 in PANC-1 cells involved in the pathogenesis of pancreatic cancer.
 

Author(s): Jun Li, Zhuoyu Gu, Siyuan Li, Zhiwei Xiao, Kan Sun

Journal:

 

Steps in the genetic basis of pancreatic cancer (PC) have been recently identified, however, Studies focusing on the relationship between Jab1 and Smad4 in PC are rarely reported. This study was performed to examine the expression patterns and association of Jab1 and Smad4 in PC cells ...

Last Updated: 14 Oct 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 6 free, full-text review articles on human participants. First 3 results:

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
 

Author(s): Doudou Li, Changhao Chen, Yu Zhou, Rufu Chen, Xinxiang Fan, Zhuofei Bi, Zhihua Li, Yimin Liu

Journal: Medicine (Baltimore). 2015 Sep;94(35):e1345.

 

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM.Summary ...

Last Updated: 4 Sep 2015

Go To URL
S-1 in the treatment of pancreatic cancer.
 

Author(s): Kentaro Sudo, Kazuyoshi Nakamura, Taketo Yamaguchi

Journal: World J. Gastroenterol.. 2014 Nov;20(41):15110-8.

 

S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported ...

Last Updated: 11 Nov 2014

Go To URL
Involvement of substance P and the NK-1 receptor in pancreatic cancer.
 

Author(s): Miguel Muñoz, Rafael Coveñas

Journal: World J. Gastroenterol.. 2014 Mar;20(9):2321-34.

 

Pancreatic cancer is the fourth leading cause of cancer related-death for both men and women and the 1- and 5-year relative survival rates are 25% and 6%, respectively. Thus, it is urgent to investigate new antitumor drugs to improve the survival of pancreatic cancer patients. The ...

Last Updated: 7 Mar 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Screening for PDAC in BRCA1/2 Patients
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 8 Apr 2016

Go to URL
Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining
 

Status: Recruiting

Condition Summary: Pancreatic Cancer

 

Last Updated: 4 Sep 2016

Go to URL
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
 

Status: Not yet recruiting

Condition Summary: Unresectable Pancreatic Cancer

 

Last Updated: 25 Oct 2016

Go to URL